Patents by Inventor Isabel Klier
Isabel Klier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240158530Abstract: The present invention relates to preparations and methods for treating a GD2 positive cancer by administering a preparation comprising a chimeric or humanized anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with Interleukin-2 (IL-2wherein a GD2 positive cancer is treated in the patient. Furthermore, the invention relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein a preparation comprising an anti-GD2 antibody is administered to the patient as a continuous infusion, without concomitantly administering IL-2. The present invention further relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein the one or more anti-GD2 antibody treatment periods is/are preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.Type: ApplicationFiled: March 6, 2023Publication date: May 16, 2024Applicant: APEIRON BIOLOGICS AGInventors: Hans LOIBNER, Oliver MUTSCHLECHNER, Ruth LADENSTEIN, Isabel KLIER
-
Patent number: 11597775Abstract: The present invention relates to preparations and methods for treating a GD2 positive cancer by administering a preparation comprising a chimeric or humanized anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with Interleukin-2 (IL-2 wherein a GD2 positive cancer is treated in the patient. Furthermore, the invention relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein a preparation comprising an anti-GD2 antibody is administered to the patient as a continuous infusion, without concomitantly administering IL-2. The present invention further relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein the one or more anti-GD2 antibody treatment periods is/are preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.Type: GrantFiled: November 28, 2017Date of Patent: March 7, 2023Assignee: APEIRON BIOLOGICS AGInventors: Hans Loibner, Oliver Mutschlechner, Ruth Ladenstein, Isabel Klier
-
Patent number: 11492412Abstract: A method of treating a high-risk neuroblastoma in a patient is described.Type: GrantFiled: March 3, 2021Date of Patent: November 8, 2022Assignee: APEIRON BIOLOGICS AGInventors: Hans Loibner, Oliver Mutschlechner, Ruth Ladenstein, Isabel Klier
-
Publication number: 20210221909Abstract: A method of treating a high-risk neuroblastoma in a patient is described.Type: ApplicationFiled: March 3, 2021Publication date: July 22, 2021Applicant: APEIRON BIOLOGICS AGInventors: Hans LOIBNER, Oliver MUTSCHLECHNER, Ruth LADENSTEIN, Isabel KLIER
-
Patent number: 10995147Abstract: A method of treating a high-risk neuroblastoma in a patient is described.Type: GrantFiled: July 6, 2020Date of Patent: May 4, 2021Assignee: APEIRON BIOLOGICS AGInventors: Hans Loibner, Oliver Mutschlechner, Ruth Ladenstein, Isabel Klier
-
Publication number: 20200332021Abstract: A method of treating a high-risk neuroblastoma in a patient is described.Type: ApplicationFiled: July 6, 2020Publication date: October 22, 2020Applicant: APEIRON BIOLOGICS AGInventors: Hans LOIBNER, Oliver MUTSCHLECHNER, Ruth LADENSTEIN, Isabel KLIER
-
Publication number: 20200055953Abstract: Preparations and methods for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with Interleukin-2 (IL-2), and wherein one or more treatment periods with the antibody may be preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.Type: ApplicationFiled: April 4, 2019Publication date: February 20, 2020Inventors: Hans Loibner, Oliver Mutschlechner, Ruth Ladenstein, Isabel Klier
-
Patent number: 10294305Abstract: Preparations and methods for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with Interleukin-2 (IL-2), and wherein one or more treatment periods with the antibody may be preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.Type: GrantFiled: February 18, 2014Date of Patent: May 21, 2019Assignee: APEIRON BIOLOGICS AGInventors: Hans Loibner, Oliver Mutschlechner, Ruth Ladenstein, Isabel Klier
-
Publication number: 20180258183Abstract: The present invention relates to preparations and methods for treating a GD2 positive cancer by administering a preparation comprising a chimeric or humanized anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with Interleukin-2 (IL-2 wherein a GD2 positive cancer is treated in the patient. Furthermore, the invention relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein a preparation comprising an anti-GD2 antibody is administered to the patient as a continuous infusion, without concomitantly administering IL-2. The present invention further relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein the one or more anti-GD2 antibody treatment periods is/are preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.Type: ApplicationFiled: November 28, 2017Publication date: September 13, 2018Applicant: APEIRON BIOLOGICS AGInventors: Hans LOIBNER, Oliver MUTSCHLECHNER, Ruth LADENSTEIN, Isabel KLIER
-
Patent number: 9840566Abstract: The present invention relates to preparations and methods for treating a GD2 positive cancer by administering a preparation comprising a chimeric or humanized anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with interleukin-2 (IL-2 wherein a GD2 positive cancer is treated in the patient. Furthermore, the invention relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein a preparation comprising an anti-GD2 antibody is administered to the patient as a continuous infusion, without concomitantly administering IL-2. The present invention further relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein the one or more anti-GD2 antibody treatment periods is/are preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.Type: GrantFiled: November 21, 2014Date of Patent: December 12, 2017Assignee: APEIRON BIOLOGICS AGInventors: Hans Loibner, Oliver Mutschlechner, Ruth Ladenstein, Isabel Klier
-
Publication number: 20160304620Abstract: The present invention relates to preparations and methods for treating a GD2 positive cancer by administering a preparation comprising a chimeric or humanized anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with interleukin-2 (IL-2 wherein a GD2 positive cancer is treated in the patient. Furthermore, the invention relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein a preparation comprising an anti-GD2 antibody is administered to the patient as a continuous infusion, without concomitantly administering IL-2. The present invention further relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein the one or more anti-GD2 antibody treatment periods is/are preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.Type: ApplicationFiled: November 21, 2014Publication date: October 20, 2016Applicant: APEIRON BIOLOGICS AGInventors: Hans LOIBNER, Oliver MUTSCHLECHNER, Ruth LADENSTEIN, Isabel KLIER
-
Publication number: 20140170155Abstract: Preparations and methods for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with Interleukin-2 (IL-2), and wherein one or more treatment periods with the antibody may be preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.Type: ApplicationFiled: February 18, 2014Publication date: June 19, 2014Applicant: APEIRON BIOLOGICS AGInventors: Hans Loibner, Oliver Mutschlechner, Ruth Ladenstein, Isabel Klier
-
Publication number: 20040180103Abstract: The present invention relates to the use of plants of the genus Hypericum or their extracts, respectively, for facilitating synchronization of a circadian rhythm with an external timer, such as in light-dark changes, day-night rhythm changes, time shifts, as occur in the case of long-distance air travel, and the so-called jetlag. The use of extracts from Hypericum perforatum is, however, also suited for use, for example, in cases of forced modifications of the rhythm of activity in persons working shifts. In order to alleviate jetlag symptoms, a dose of 2-200 mg per kg body weight was found to be preferred.Type: ApplicationFiled: May 10, 2004Publication date: September 16, 2004Inventors: Gerhard Heldmaier, Isabel Klier, Tatjana Patzelt